跳至主要内容
临床试验/ISRCTN14326006
ISRCTN14326006已完成3 期

Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada

niversity Health Network0 个研究点目标入组 13 人开始时间: 2020年4月14日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
13

研究概览

简要总结

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/32665039/ structured summary of protocol (added 17/07/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Health care worker (HCW) in the emergency department who is anticipated to work at least 10 shifts over the duration of the study period (minimum 6 hours per shift) and anticipated to remain in the emergency department for the duration of the study (i.e., not transferring to another unit). For the purposes of the study, health care workers” are physicians (including residents), nurses, nurse practitioners, physician assistants, respiratory therapists, X-ray technicians, social workers and support staff (including but not limited to house-keeping, and porters)
  • 2. Age =18 years
  • 3. Ability to communicate with study staff in English

排除标准

  • 1. Currently pregnant, planning to become pregnant during the study period, and/or breast feeding
  • 2. Known hypersensitivity/allergy to hydroxychloroquine or to 4-aminoquinoline compounds.
  • 3. Current use of hydroxychloroquine for the treatment of a medical condition.
  • 4. Known prolonged QT syndrome, or concomitant medications which simultaneously may prolong the QTC that cannot be temporarily suspended/replaced. These are including but not limited to Class IA, IC and III antiarrhythmics; certain antidepressants, antipsychotics, and anti-infectives; domperidone; 5-hydroxytryptamine (5-HT)3 receptor antagonists; kinase inhibitors; histone deacetylase inhibitors beta-2 adrenoceptor agonists.
  • 5. Known pre-existing retinopathy.
  • 6. Disclosure of self-administered use of hydroxychloroquine or chloroquine within 12 weeks prior to study. This window allows five half-lives of HCQ (i.e. 21 days) to pass before being reintroduced to the drug.
  • 7. Confirmed symptomatic COVID-19 at time of enrollment, i.e. symptom of COVID-19 at enrollment with confirmation of SARS-CoV-2 infection by viral detection as performed according to local guidelines for symptomatic HCWs. All participants with COVID-19 symptoms at enrollment will be directed to have confirmatory testing (within the department or occupational health as per the site guidelines). Participants who are negative for SARS-CoV-2 will be redirected to enrollment procedures; those testing positive will be excluded.

研究者

发起方
niversity Health Network

相似试验